CSTL Castle Biosciences Inc

Price (delayed)

$19.44

Market cap

$533.63M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.14

Enterprise value

$450.1M

Castle Biosciences is a commercial-stage dermatologic cancer company focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The Company currently ...

Highlights
The gross profit has soared by 66% YoY and by 17% from the previous quarter
CSTL's revenue has soared by 60% YoY and by 14% from the previous quarter
Castle Biosciences's quick ratio has decreased by 24% YoY and by 20% QoQ
The debt has increased by 15% YoY and by 5% QoQ

Key stats

What are the main financial stats of CSTL
Market
Shares outstanding
27.45M
Market cap
$533.63M
Enterprise value
$450.1M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.34
Price to sales (P/S)
2.37
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.05
Earnings
Revenue
$219.79M
EBIT
-$57.35M
EBITDA
-$45.02M
Free cash flow
-$19.23M
Per share
EPS
-$2.14
Free cash flow per share
-$0.72
Book value per share
$14.54
Revenue per share
$8.2
TBVPS
$12.54
Balance sheet
Total assets
$453.34M
Total liabilities
$62.07M
Debt
$15.31M
Equity
$391.27M
Working capital
$247.97M
Liquidity
Debt to equity
0.04
Current ratio
6.2
Quick ratio
5.93
Net debt/EBITDA
1.86
Margins
EBITDA margin
-20.5%
Gross margin
79.5%
Net margin
-26.1%
Operating margin
-30.9%
Efficiency
Return on assets
-13.2%
Return on equity
-14.9%
Return on invested capital
-29.9%
Return on capital employed
-14.1%
Return on sales
-26.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CSTL stock price

How has the Castle Biosciences stock price performed over time
Intraday
0.67%
1 week
1.09%
1 month
-4.09%
1 year
-20.1%
YTD
-9.92%
QTD
-12.23%

Financial performance

How have Castle Biosciences's revenue and profit performed over time
Revenue
$219.79M
Gross profit
$174.81M
Operating income
-$67.98M
Net income
-$57.47M
Gross margin
79.5%
Net margin
-26.1%
The gross profit has soared by 66% YoY and by 17% from the previous quarter
CSTL's revenue has soared by 60% YoY and by 14% from the previous quarter
The operating margin has surged by 54% year-on-year and by 31% since the previous quarter
The net margin has increased by 47% YoY and by 34% QoQ

Growth

What is Castle Biosciences's growth rate over time

Valuation

What is Castle Biosciences stock price valuation
P/E
N/A
P/B
1.34
P/S
2.37
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.05
CSTL's EPS is up by 25% since the previous quarter and by 17% year-on-year
CSTL's price to book (P/B) is 58% lower than its 5-year quarterly average of 3.2 but 2.3% higher than its last 4 quarters average of 1.3
The P/S is 77% below the 5-year quarterly average of 10.2 and 16% below the last 4 quarters average of 2.8
CSTL's revenue has soared by 60% YoY and by 14% from the previous quarter

Efficiency

How efficient is Castle Biosciences business performance
Castle Biosciences's return on invested capital has surged by 57% YoY and by 27% QoQ
CSTL's return on sales is up by 48% year-on-year and by 34% since the previous quarter
The ROE rose by 24% QoQ and by 10% YoY
Castle Biosciences's return on assets has increased by 24% QoQ and by 11% YoY

Dividends

What is CSTL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CSTL.

Financial health

How did Castle Biosciences financials performed over time
The total liabilities has grown by 29% year-on-year and by 24% since the previous quarter
Castle Biosciences's quick ratio has decreased by 24% YoY and by 20% QoQ
The debt is 96% lower than the equity
CSTL's debt to equity is up by 33% year-on-year
The debt has increased by 15% YoY and by 5% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.